The Mission Report


Biotech Showcase 2013 Conference
EBD Group – January 7th - 9th, 2013

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Presenting Companies

 

Addex Therapeutics (ADDXF)

Addex Therapeutics (OTC: ADDXF) focuses on the discovery and development of an emerging class of oral small molecule drugs that can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. ADDXF’s two lead products are being investigated in three phase IIa clinical studies: dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia; and ADX71149 to treat schizophrenia and anxiety. For further information, visit the company's Web site at www.addextherapeutics.com

Advanced Cell Technology Inc. (ACTC)

Advanced Cell Technology Inc. (OTC: ACTC) is a biotech company that applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine. ACTC is also developing therapeutic platforms using corneal endothelial cells for use in treating corneal blindness, as well as retinal neural progenitor cells for use in treating glaucoma. For further information, visit the company's Web site at www.advancedcell.com

Aethlon Medical Inc. (AEMD)

Aethlon Medical Inc. (OTC: AEMD) is a development stage medical device company focused on creating devices for the treatment of cancer, infectious diseases and other life-threatening conditions. The company’s Aethlon Hemopurifier is intended for the treatment of cancer, hepatitis-C virus, human immunodeficiency virus (HIF), and bioterror and pandemic threats. It also develops ELLSA to identify the presence of exosomes underlying the HIV, tuberculosis and various types of cancer. For further information, visit the company’s Web site at: www.aethlonmedical.com

Allied Healthcare Group (BOMDF)

Allied Healthcare Group (OTC: BOMDF) is a diversified healthcare company focused on investing in next generation technologies, acquiring strategic assets to grow its product and service offerings. BOMDF operates in three businesses: Cordion, focused on vaccine technology for the prevention of infectious diseases and cancer; Celxcel, for the clinical development of regenerative tissue engineering technologies; and Allied Medical, for the sales and distribution of niche medical technologies. For further information, visit the company's Web site at www.alliedhealthcaregroup.com.au

Alliqua Inc. (ALQA)

Alliqua Inc. (OTC: ALQA) is a biomedical company focused on the development, manufacturing and marketing of its own proprietary products based on the company’s existing technology portfolio. ALQA currently markets its own proprietary brands of wound dressings: SilverSeal® Hydrogel, an antimicrobial dressing; and Hydress®, a moist wound dressing. The company’s core transdermal delivery technology platform is designed to deliver drugs and other beneficial ingredients through the skin. For further information, visit the company's Web site at www.alliqua.com

Amarantus Bioscience Inc. (AMBS)

Amarantus Bioscience Inc. (OTC: AMBS) is a development-stage biotech company focused on the discovery and development of therapeutic proteins and biologics for the treatment of Parkinson’s disease, traumatic brain injury (TBI) and other human diseases. The company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), which corrects protein misfolding. For further information, visit the company’s Web site at: www.amarantus.com

Amorcyte, a NeoStem company (NBS)

Amorcyte, a NeoStem company (NYSE: NBS), is a biopharm company engaged in the development of proprietary cellular therapies in cardiovascular disease, immunology and regenerative medicine primarily in the United States. Its lead product candidate, AMR-001, which is for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. For further information, visit the company’s Web site at www.neostem.com

Amorfix Life Sciences Ltd. (ARFXF)

Amorfix Life Sciences Ltd. (OTC: ARFXF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer and Alzheimer's Disease. The company offers two types of products: therapeutics, designed to target and neutralize only the misfolded conformation of a given protein; and diagnostic services using its highly sensitive and specific diagnostic kits. For further information, visit the company's Web site at www.amorfix.com

AmpliPhi Biosciences Corp. (APHB)

AmpliPhi Biosciences Corp. (OTC: APHB) is a biotech company engaged in the development of anti-bacterial solutions to enhance human health through the application of its proprietary bacteriophage platform. Its lead product development programs target gram negative bacterial infections that are resistant to antibiotic treatments. They include BioPhage-PA for the treatment of chronic inner ear infections and BioPhage-PR for the treatment of lung infections in cystic fibrosis patients. For further information, visit the company’s Web site at www.targen.com

Aradigm Corp. (ARDM)

Aradigm Corp. (OTC: ARDM) is engaged in developing inhalation drug products designed to improve the quality of life of patients with severe pulmonary disease. The company's lead development candidates are formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100), which is delivered by inhalation for the management of infections associated with the severe respiratory diseases cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). For further information, visit the company's Web site at www.aradigm.com

Astex Pharmaceuticals Inc. (ASTX)

Astex Pharmaceuticals Inc. (NASDAQ: ASTX) is an innovative drug discovery, development and commercialization company focusing on therapeutics to fight against cancer and other life-threatening diseases. The company’s primary areas of focus are oncology and hematology. ASTX has established a broad pipeline of small molecule, molecularly targeted drugs using its drug discovery engine, Pyramid™. For further information, visit the company's Web site at www.astx.com

Athersys Inc. (ATHX)

Athersys Inc. (NASDAQ: ATHX) is a clinical stage biopharm company growing a pipeline of highly differentiated therapeutics to treat significant and life-threatening diseases. The company’s current product development portfolio consists of MultiStem®, a proprietary stem cell product for the treatment of multiple disease indications, which is currently being evaluated in several clinical trials. For further information, visit the company's Web site at www.athersys.com

Atossa Genetics Inc. (ATOS)

Atossa Genetics Inc. (NASDAQ: ATOS) is a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. For further information, visit the company's Web site at www.atossagenetics.com

Avita Medical Ltd. (AVMXF)

Avita Medical Ltd. (OTC: AVMXF) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. The company's lead product, ReCell® Spray-On Skin™, is CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. In the U.S. ReCell is an investigational device limited by federal law to investigational use; a phase 3 FDA trial is in process. For further information, visit the company's Web site at www.avitamedical.com

Bavarian Nordic A/S (BVNKF)

Bavarian Nordic A/S (OTC: BVNKF) is a vaccine-focused biotech company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer and the subject of an ongoing pivotal phase 3 trial. In infectious diseases, BVNKF’s lead program is IMVAMUNE®, a non-replicating smallpox vaccine. For further information, visit the company's Web site at www.bavarian-nordic.com

Bio-Path Holdings Inc. (BPTH)

Bio-Path Holdings Inc. (OTC: BPTH) is a biotech company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology, which was designed to systemically distribute nucleic acid drugs throughout the human body via intravenous infusion. BPTH is primarily focused on cancer; its lead product candidate, Liposomal Grb-2, is in a phase I study for blood cancers. The company’s second drug candidate is ready for clinical evaluation for lymphoma and solid tumors. For further information, visit the company's Web site at www.biopathholdings.com

Bioniche Life Sciences (BNHLF)

Bioniche Life Sciences (OTC: BNHLF) is a research-based biopharm company that discovers, develops, manufactures and markets proprietary products for human and animal health markets. The company operates three global business divisions: human health, animal health and food safety. BNC’s Urocidin™ is a formulation of Mycobacterial Cell Wall-DNA Complex (MCC) for the treatment of bladder cancer. A phase 3 clinical program is underway, in partnership with Endo Pharmaceuticals Inc. For further information, visit the company's Web site at www.bioniche.com

Bionomics Ltd. (BMICY)

Bionomics Ltd. (OTC: BMICY) is a drug discovery and development company focused on new treatments for cancer and serious disorders of the central nervous system (CNS). The company utilizes its technology platforms with the aim of identifying and developing therapies to treat cancer and conditions of the CNS, including anxiety, multiple sclerosis and epilepsy. In September 2012, BMICY acquired Eclipse Therapeutics Inc. For further information, visit the company's Web site at www.bionomics.com/au

Cardium Therapeutics Inc. (CXM)

Cardium Therapeutics Inc. (NYSE: CXM) is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs. The company’s current medical opportunities portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's newly acquired To Go Brands healthy nutraceutical supplement business. For further information, visit the company's Web site at www.cardiumthx.com

Cipher Pharmaceuticals Inc. (CPHMF)

Cipher Pharmaceuticals Inc. (OTC: CPHMF) is a specialty pharmaceutical company that develops improved formulations of existing drugs using drug delivery technologies. The company has three products, all of which are approved by the FDA: Lipofen® for the treatment of high cholesterol; ConZip®/Durela® for the treatment of moderate to moderately severe pain; and Cip-Isotretinoin for the treatment of severe acne. For further information, visit the company's Web site at www.cipherpharma.com

Circadian Technologies Ltd. (CKDXF)

Circadian Technologies Ltd. (OTC: CKDXF) is engaged in angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs), the company seeks to develop truly novel therapies to extend and improve the lives of cancer sufferers. The company’s intellectual property rights include more than 50 patent families, 200 granted patents and 500 patents pending. The company’s most advanced program, VGX-100, an antibody-drug targeting VEGF-C, is expected to enter clinical trials in 2011. For further information, visit the company's Web site at www.circadian.com.au

CollabRX Inc. (CLRX)

CollabRX Inc. (NASDAQ: CLRX) is a data analytics company that uses cloud-based expert systems to inform healthcare decision-making. CLRX’s CollabRx Therapy Finders is a series of Web-based applications that provide information to physicians and patients for determining which medical tests, therapies and clinical trials considered in cancer treatment planning. The company was formerly known as Tegal Corp. and changed its name to CollabRx Inc. in September 2012. For further information, visit the company's Web site at www.collabrx.com

Cryoport Inc. (CYRX)

Cryoport Inc. (OTC: CYRX) provides cold chain frozen shipping systems primarily to the biotechnology, pharmaceutical and life science industries worldwide. CYRX offers reusable cryogenic transport containers for the transportation of biological, environmental and other temperature sensitive materials. The company’s products include CryoPort Express Shipper, a dry cryogenic shipper that uses liquid nitrogen contained inside a vacuum insulated bottle to provide stable storage temperatures. For further information, visit the company’s Web site at www.cryoport.com

Cyclacel Pharmaceuticals Inc. (CYCC)

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) is a biopharmaceutical company developing oral therapies for the treatment of cancer and other serious diseases. The company has three product candidates are currently in clinical development: Sapacitabine (CYC682) for the treatment of acute myeloid leukemia (AML) in the elderly and for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia; Seliciclib (CYC202) for the treatment of lung cancer and nasopharyngeal cancer; and CYC116 for patients with solid tumors. For further information, visit the company's Web site at www.cyclacel.com

CytoDyn Inc. (CYDY)

CytoDyn Inc. (OTC: CYDY) is a biotech company focused on developing new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate PRO 140 is a humanized monoclonal antibody which has demonstrated the ability to block the entry of HIV virus into human white cells. PRO 140 has completed phase I and phase 2a human clinical trials. For further information, visit the company's Web site at www.cytodyn.com

Cytori Therapeutics Inc. (CYTX)

Cytori Therapeutics Inc. (NASDAQ: CYTX) is a medical technologies company focused on the potential of adult stem cell and regenerative cells from adipose tissue. The company’s Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets while awaiting FDA approval in the United States. CYTX’s StemSource® product line is sold globally for cell banking and research applications. For further information, visit the company's Web site at www.cytori.com

CytRx Corp. (CYTR)

CytRx Corp. (NASDAQ: CYTR) is a biopharm research and development company specializing in oncology. Its product pipeline includes INNO-206, in phase Ib clinical trial and completing phase Ib/2 clinical trial for the treatment for soft tissue sarcomas; tamibarotene, in phase 2b clinical trial for the treatment of non-small-cell lung cancer and in a clinical trial as a treatment for acute promyelocytic leukemia; and bafetinib, in phase 2 clinical trial for the treatment of high-risk B-cell chronic lymphocytic leukemia. For further information, visit the company's Web site at www.cytrx.com

Echo Therapeutics Inc. (ECTE)

Echo Therapeutics Inc. (NASDAQ: ECTE) is a transdermal medical device company specializing in skin permeation technology. The company is developing its Prelude® SkinPrep System as a platform technology to allow for significantly enhanced and painless skin permeation that will enable needle-free drug delivery and analyte extraction. ECTE also engages in the development of specialty pharmaceuticals based on its proprietary AzoneTS transdermal drug reformulation technology. For further information, visit the company's Web site at www.echotx.com

ERBA Diagnostics Inc. (ERB)

ERBA Diagnostics Inc. (NYSE: ERB) is an emerging company in the global healthcare industry, operating in the core business segment of In Vitro Diagnostics (IVD). ERB’s product range includes a wide range of Clinical Chemistry Analyzers (Photometers & Fully Automated), Haematology analyzers, Urine Strips & Analyzers, Electrolyte Analyzer, Microplate ELISA Readers and Washers, range of Clinical Chemistry, Immunoturbidimetry and Immunology Reagents, Pipettes and Consumables. For further information, visit the company's Web site at www.erbamannheim.com

Fluoropharma (FPMI)

Fluoropharma (OTC: FPMI) is engaged in the discovery, development and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology. The company’s BFPET is in phase I trial used for the detection of ischemic and infarcted tissue within the myocardium in patients with suspected or proven chronic CAD. CardioPET is in phase II development stage for the assessment of myocardial metabolism. For further information, visit the company’s Web site at: www.fluoropharma.com

Genmab A/S (GNMSF)

Genmab A/S (OTC: GNMSF) is a biotech company engaged in the development of human antibody therapeutics for the treatment of cancer in Denmark and internationally. The company has one product on the market, ofatumumab, and is developing a pipeline of fully human antibody therapeutics for the treatment of cancer. Genmab’s clinical product pipeline includes ofatumumab, daratumumab (HuMax® -CD38) and RG1512 (developed under collaboration with Roche). For further information, visit the company’s Web site at www.genmab.com

ImmunoCellular Therapeutics (IMUC)

ImmunoCellular Therapeutics (NYSE: IMUC) is a clinical-stage biotech company focused on the development of novel immune-based products for the treatment of cancer. The product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat cancers such as glioblastoma multiforme (GBM), ovarian cancer, small-cell lung cancer and pancreatic cancer. For further information, visit the company's Web site at www.imuc.com

ImmunoVaccine Inc. (IMMVF)

ImmunoVaccine Inc. (OTC: IMMVF) is a clinical-stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy, infectious diseases and animal health. The company’s pipeline also includes a broad range of infectious diseases programs including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. For further information, visit the company's Web site at www.imvaccine.com

Inovio Pharmaceuticals Inc. (INO)

Inovio Pharmaceuticals Inc. (NYSE: INO) is engaged in the development of synthetic vaccines, with a focus on cancers and infectious diseases. The company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against pathogens, such as influenza and human immunodeficiency virus (HIV). INO’s clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. For further information, visit the company's Web site at www.inovio.com

International Stem Cell Corp. (ISCO)

International Stem Cell Corp. (OTC: ISCO), a development-stage biotech company, focuses on the development and commercialization of therapeutic, biomedical and cosmeceutical products based on human parthenogenetic stem cells. It also develops, manufactures and markets anti-aging skin care products. In addition, ISCO produces and sells human cell culture products to research scientists for use in pharmaceutical, academic and government research organizations. For further information, visit the company's Web site at www.internationalstemcell.com

InVivo Therapeutics (NVIV)

InVivo Therapeutics (OTC: NVIV) is focused on developing and commercializing technologies for the treatment of spinal cord injuries (SCI). The company’s aim is to develop/commercialize biocompatible polymer scaffolding devices to treat acute spinal cord injuries; biocompatible hydrogel to treat acute spinal cord injuries and peripheral nerve injuries; and biocompatible polymer scaffolding devices seeded with autologous human neural stem cells to treat acute and chronic spinal cord injuries. For further information, visit the company's Web site at www.invivotherapeutics.com

MDxHealth SA (MXDHF)

MDxHealth SA (OTC: MXDHF) is a molecular diagnostics company that develops and commercializes advanced epigenetic tests to support cancer treatment. The company utilizes its proprietary, patented DNA methylation platform and biomarkers to offer tests that aid in the improvement of cancer diagnostics, prognosis and treatments for multiple cancer types. For further information, visit the company's Web site at www.mdxhealth.com

Medbox Inc. (MDBX)

Medbox Inc. (OTC: MDBX), through its subsidiary Prescription Vending Machines Inc., engages in developing a patented machine that dispenses medication to individuals based on biometric identification. The company’s flagship product is MedBox, an automated medicine dispensing machine that utilizes biometrics to identify users before dispensing and electronics to verify that the physician’s recommendation remains active. For further information, visit the company's Web site at www.medboxinc.com

MetaStat Inc. (MTST)

MetaStat Inc. (OTC: MTST) is a life science company operating through its subsidiary MetaStat BioMedical to develop and commercialize proprietary clinical diagnostic tests that predict the probability of blood borne systemic metastasis of cancer; and therapeutics to prevent systemic metastasis. Its products include MetaSite Breast test; MenaCalc Breast test; MenaCalc Lung test; MenaCalc Prostate test; and MenaBloc therapeutics to reduce or eliminate metastasis. For further information, visit the company's Web site at www.metastat.com

MRI Interventions Inc. (MRIC)

MRI Interventions Inc. (OTC: MRIC) is a medical device company that develops and commercializes platforms for procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company has two product platforms: ClearPoint, in commercial use in the U.S. to perform minimally invasive surgical procedures in the brain; and ClearTrace, still in development, to perform minimally invasive surgical procedures in the heart. For further information, visit the company's Web site at www.mriinterventions.com

Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals (NYSE: NAVB) is a biopharm company focused on the development and commercialization of precision diagnostic agents. NAVB’s radiopharmaceutical development programs include Lymphoseek, a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent; and RIGScan, a tumor antigen-specific targeting agent. The company has a license agreement for Altropane, being developed as an aid in the diagnosis of Parkinson’s disease, movement disorders and dementia. For further information, visit the company's Web site at www.navidea.com

Neuralstem Inc. (CUR)

Neuralstem Inc. (NYSE: CUR), a development-stage company focused on the development and commercialization of treatments for central nervous system disease, has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. CUR’s aim is to develop methods to generate replacement cells from neural stem cells. For further information, visit the company's Web site at www.neuralstem.com

NovaBay Pharmaceuticals Inc. (NBY)

NovaBay Pharmaceuticals Inc. (NYSE: NBY) is a clinical-stage biotech company focused on the development of its proprietary and patented Aganocide® compounds. NBY focuses its technology on four therapeutic areas: dermatology, ophthalmology, urology and hospital infections. The company has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. For further information, visit the company's Web site at www.novabay.com

Ohr Pharmaceutical Inc. (OHRP)

Ohr Pharmaceutical Inc. (OTC: OHRP) is engaged in the development of novel therapeutics for the treatment of serious and unmet medical needs. The company’s lead compounds include OHR/AVR 118 for the treatment of cancer cachexia, and Squalamine eye drops for the treatment of the wet form of age-related macular degeneration and other ophthalmic neovascularization disorders. For further information, visit the company's Web site at www.ohrpharmaceutical.com

OncoSec Medical Inc. (ONCS)

OncoSec Medical Inc. (OTC: ONCS) is a biotech company focused on the development of treatments addressing advanced-stage skin cancer, specifically: melanoma, Merkel cell lymphoma and cutaneous T-cell lymphoma. ONCS’ proprietary technology, OncoSec Medical System™ (OMS), is based on electroporation and in pre-clinical and clinical data demonstrated safety and efficacy. OMS is undergoing a phase II study for patients with late-stage metastatic melanoma. For further information, visit the company's Web site at www.oncosec.com

Organovo Holdings Inc. (ONVO)

Organovo Holdings Inc. (OTC: ONVO) focuses on breakthrough 3D biology capabilities to create tissue on-demand for research and surgical applications. The company’s NovoGen MMX Bioprinter™ is the world’s only commercial bioprinter with the proven ability to create tissue. The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently. For further information, visit the company's Web site at www.organovo.com

Pressure BioSciences Inc. (PBIO)

Pressure BioSciences Inc. (OTC: PBIO) engages in the development and commercialization of pressure cycling technology (PCT), a patented, enabling technology platform with multiple applications in the life sciences sample preparation market. PBIO’s focus is on the development and sale of PCT-enhanced sample preparation systems for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology and counter-bioterror applications. For further information, visit the company’s Web site at: www.pressurebiosciences.com

ProMetic Life Sciences (PFSCF)

ProMetic Life Sciences (OTC: PFSCF) operates through a group of subsidiaries to specialize in the design of small molecules that mimic unique and specific interactions between proteins. The company’s technologies are applicable to large-scale drug purification, drug development, proteomics and the elimination of pathogens. PLI is also developing novel therapeutics targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer, and autoimmune disease/inflammation as well as certain nephropathies. For further information, visit the company's Web site at www.prometic.com

ReNeuron Group (RNUGF)

ReNeuron Group (OTC: RNUGF) is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications worldwide. Its lead therapeutic candidate is ReN001 stem cell therapy, which is in clinical development stage for the treatment of patients left disabled by the effects of a stroke. The company also develops ReN009 stem cell therapy to treat peripheral arterial disease; and ReN003 programme for blindness-causing diseases. For further information, visit the company’s Web site at www.reneuron.com

Repros Therapeutics Inc. (RPRX)

Repros Therapeutics Inc. (NASDAQ: RPRX) is a development stage biopharmaceutical company focused on the development of oral small molecule drugs for major unmet medical needs in male and female health. The company’s current product pipeline includes Androxal®, in phase 2 trials for male reproductive health; and Proellex®, which is on partial clinical hold status per the FDA, for female reproductive health. For further information, visit the company's Web site at www.zonagen.com

Resverlogix Corp. (RVXCF)

Resverlogix Corp. (OTC: RVXCF) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is developing RVX-208 for the treatment of atherosclerosis. RVX’s business model is to seek strategic opportunities through early alliance partnerships with the potential to bring its technology platforms to successful commercialization. For further information, visit the company's Web site at www.resverlogix.com

Retrophin (RTRX)

Retrophin (OTC: RTRX) is a biotech company focused on discovering and developing treatments for rare and life-threatening diseases. RTRX is currently developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. The company’s lead compound, RE-021, formerly known as DARA, is scheduled to begin enrollment in a potentially pivotal phase 2 clinical trial for FSGS in 1H13. For further information, visit the company's Web site at www.retrophin.com

RXi Pharmaceuticals Corp. (RXII)

RXi Pharmaceuticals Corp. (OTC: RXII) is a biotech company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. RXi’s first RNAi product candidate, RXI-109, entered into RXi’s first human clinical trial in 2012. The candidate is initially being developed to reduce or inhibit scar formation in the skin following surgery. For further information, visit the company's Web site at www.rxipharma.com

Senesco Technologies Inc. (SNTI)

Senesco Technologies Inc. (OTC: SNTI) is a provider of proven energy efficiency technology for commercial organizations. Sabien's M2G and M3G products are proven to reduce carbon emissions and energy consumption by between 10% and 25% with typical paybacks in less than two years. The company’s wholly owned subsidiaries include Sabien Technology Ltd. and Sabien Technology IP ltd. For further information, visit the company's Web site at www.sabien-tech.co.uk

Sernova Corp. (SEOVF)

Sernova Corp. (OTC: SEOVF) is a clinical-stage company developing products that provide a natural and immune-protected environment for delivering therapeutic cells to patients. The company is developing two novel closely integrated proprietary platform technologies: Cell Pouch System™ and Sertolin™. SVA’s products may benefit patients with chronic metabolic, neurological, and haematological diseases. For further information, visit the company's Web site at www.sernova.com

Shire (SHPG)

Shire (NASDAQ: SHPG) is a biopharmaceutical company that focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas. SHPG’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. For further information, visit the company's Web site www.shire.com

SpectraScience Inc. (SCIE)

SpectraScience Inc. (OTC: SCIE) is a medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The company’s WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. For further information, visit the company's Web site at www.spectrascience.com

Stellar Biotechnologies Inc. (SBOTF)

Stellar Biotechnologies Inc. (OTC: SBOTF) produces and markets keyhole limpet hemocyanin (KLH), as well as develops technology related to the culture and production of KLH and KLH subunit formulations in the United States and Europe. The company’s KLH is an immunogenic high-molecular-weight protein, which is used in cancer and therapeutic vaccines for lymphoma, bladder, breast, colon, sarcoma, small cell lung cancer, Alzheimer’s disease, rheumatoid arthritis, lupus and post-traumatic stress disorder chemical dependencies. For further information, visit the company's Web site www.stellarbiotechnologies.com

Sucampo Pharmaceuticals (SCMP)

Sucampo Pharmaceuticals (NASDAQ: SCMP) is a global pharmaceutical company engaged in the development and commercialization of medicines based on prostones, a class of compounds occurring naturally in the body. The company is focused on developing prostone-based compounds for the treatment of gastrointestinal, ophthalmic, vascular and respiratory diseases as well as other disorders for which there are significant unmet medical needs, underserved patients and significant commercial potential. For further information, visit the company's Web site at www.sucampo.com

Tvax Biomedical Inc. (TVAX)

Tvax Biomedical Inc. (NASDAQ: TVAX) is a clinical stage drug development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. The company’s lead candidates, focused on treating brain and kidney cancer, are supported by positive phase 2 clinical data and extensive preclinical and phase 1 safety studies. The FDA has authorized the company to initiate pivotal phase 3 clinical trials for both drug candidates to support their potential FDA approval. For further information, visit the company's Web site at www.tvaxbiomedical.com

Venaxis Inc. (APPY)

Venaxis Inc. (NASDAQ: APPY) is a biomedical company engaged in R&D activities that primarily focus on a human acute appendicitis blood-based test. The company’s lead product candidate includes APPY1, a blood-based diagnostic test designed to aid in the evaluation of patients presenting signs and symptoms of acute appendicitis. It is also developing animal health products, including cattle and equine reproduction products. For further information, visit the company's Web site at www.venaxis.com

Viropro (VPRO)

Viropro (OTC: VPRO), through its subsidiaries, engages in the contract research, development, and manufacturing of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis. For further information, visit the company’s Web site at www.viropro.com

Virovek Inc. (VPRO)

Virovek Inc. (OTC: VPRO) operates through its four subsidiaries: California-based Biologics Processing Development for protein purification and development; Alpha Biologics in the UK for protein purification and development; Alpha Biologics Sdn BHD in Malaysia for clinical production; and Canada-based Viropro International for cloning and sequencing. The company’s primary objective is to provide high-yield development and GMP manufacturing services to biopharmaceutical companies in global markets with unmet medical and/or market needs. For further information, visit the company's Web site at www.viropro.com

Zalicus Inc. (ZLCS)

Zalicus Inc. (NASDAQ: ZLCS) is a biopharmaceutical company focused on the discovery and development of treatments against pain and immune-inflammatory diseases. The company’s internal pipeline includes Z160 for chronic neuropathic pain and Z944 for acute and inflammatory pain. ZLCS has multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. For further information, visit the company's Web site at www.zalicus.com

 
Twitter

For more frequent updates, follow us on Twitter!

Home     About Us     Blog     Investors     IR Services     Market Research     Partners     Contact     Disclaimer

© 2013 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975